ME and MY MONEY
ME and MY MONEY® provides insight and commentary on the Canadian investment marketplace.

News Sites
MONEY®
MONEY® News
ME and MY MONEY®
YOU and YOUR MONEY®

Advertising
MONEY® Video - Financial News Updates 4X a DAY!
Network Sites
1-800-789-1011
American Dollar
ADMONEY®
Advisor Channel
BACK OFFICE® Canada
Bank Funds
Best Rate Around®
Canadian Money Magazine
Coin Dealer
Financial Advertising
Financial Content
Guaranteed Investment Certificates
Independent Pension Plan
Investment Marketplace
MONEY®
MONEY® Advertising
MONEY® Clothing
MONEY® Magazine Canada
MONEY® Media
MONEY® News
MONEY® Video
MutualFund.ca
Mutual Funds Canada
The American Dollar
The MONEY® Channel
The Montreal Star
Questions - Answers
YOU and YOUR MONEY®
Blog Search
Blogroll
  • Blog
  • Centennial College
  • Dean Paley
  • Frank Wiginton
  • James Dean
  • Jorge Ramos
  • Ken Kivenko
  • Laurie Lee
  • Richie Rich
  • Ryan Wall
  • Tahnya Kristina
  • George Brown College
  • Humber College
  • Seneca College
  • Categories
    April 2010
    M T W T F S S
    « Mar   Jun »
     1234
    567891011
    12131415161718
    19202122232425
    2627282930  

    Tags

    Blogroll


    BioFinance with Gowling Lafleur Henderson Apr.6-8

    Bio Finance with Gowling Lafleur Henderson Apr.6-8

    This week’s BioFinance 2010 conference in Toronto brings light to a sector that has experienced significant challenges in 2009. With the biotechnology outlook dim, many companies were the targets of mergers and acquisitions. Part of the sector’s performance in 2009 can also be attributed to uncertainty about health care reform legislation in the United States. Given recent developments and the likelihood of a shake up within the sector, will biotechnology and medical technology be in demand for Canadian investors?

    This week’s BioFinance 2010 conference in Toronto brings light to a sector that has experienced significant challenges in 2009. With the biotechnology outlook dim, many companies were the targets of mergers and acquisitions. Part of the sector’s performance in 2009 can also be attributed to uncertainty about health care reform legislation in the United States. Given recent developments and the likelihood of a shake up within the sector, will biotechnology and medical technology be in demand for Canadian investors?

    Investors, analysts and legal professionals are looking towards next week’s conference for guidance on how this sector fairs for the remainder of 2010 and beyond. This industry may be positioned for renewed investor interest in 2010, despite the market lagging in 2009.

    Gowling Lafleur Henderson (Gowlings) was recently named one of the world’s life science patent litigation law firms. I would be happy to set up an opportunity for you to speak with Michael Herman and Bob Ford, partners in Gowlings’ business law department, who are available during and after this conference to discuss how Canadians should view the biotechnology industry in 2010 and how they see the next generation of medicine development in Canada. Both professionals work to service the particular needs of technology and life sciences companies and those investors that fund them. Please let me know if you would like to discuss this opportunity.

    The MONEY® Network